Hostname: page-component-78c5997874-t5tsf Total loading time: 0 Render date: 2024-11-10T08:44:58.928Z Has data issue: false hasContentIssue false

Human papillomavirus prevalence and clinicopathological associations in oropharyngeal squamous cell carcinoma in the Lebanese population

Published online by Cambridge University Press:  29 June 2018

R Mhawej*
Affiliation:
Department of Otolaryngology – Head and Neck Surgery, Saint Joseph University, Beirut, Lebanon
C Ghorra
Affiliation:
Department of Pathology, Hotel Dieu de France Hospital, Saint Joseph University, Beirut, Lebanon
S Naderi
Affiliation:
Department of Pathology, Hotel Dieu de France Hospital, Saint Joseph University, Beirut, Lebanon
N Khoueir
Affiliation:
Department of Otolaryngology – Head and Neck Surgery, Saint Joseph University, Beirut, Lebanon
W Abou Hamad
Affiliation:
Department of Otolaryngology – Head and Neck Surgery, Saint Joseph University, Beirut, Lebanon
A E Melkane
Affiliation:
Department of Otolaryngology – Head and Neck Surgery, Saint Joseph University, Beirut, Lebanon
*
Author for correspondence: Dr Rachad Mhawej, Department of Otolaryngology – Head and Neck Surgery, Hotel Dieu de France Hospital, Alfred Naccache Boulevard, 166830 Ashrafieh, Beirut, Lebanon E-mail: rachad.mhawej@net.usj.edu.lb

Abstract

Objectives

To evaluate for the first time the prevalence of human papillomavirus in oropharyngeal squamous cell carcinoma in a Middle-Eastern population, and to determine associations between human papillomavirus profiles and clinicopathological characteristics.

Methods

A retrospective chart review was conducted of all patients treated for oropharyngeal squamous cell carcinoma at the Hotel Dieu de France University Hospital (Beirut, Lebanon) between January 2010 and 2016. Existing formalin-fixed paraffin-embedded tumour samples were analysed. Human papillomavirus DNA viral load and p16 expression were evaluated using polymerase chain reaction and immunohistochemistry respectively.

Results

Thirty patients (mean age of 60 years) were included. Twenty-seven per cent of patients were p16-positive/human papillomavirus DNA positive, 53 per cent were p16-negative/human papillomavirus DNA negative and 20 per cent were p16-positive/human papillomavirus DNA negative. Human papillomavirus 16 was the most frequent subtype (75 per cent). Smoking and alcohol consumption were significantly lower in the human papillomavirus positive group compared to the human papillomavirus negative group (p = 0.049 and 0.004, respectively).

Conclusion

Human papillomavirus rate was lower than reported rates in Western populations. Possible explanations include differences in social and cultural behaviours.

Type
Main Articles
Copyright
Copyright © JLO (1984) Limited, 2018 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

Dr R Mhawej takes responsibility for the integrity of the content of the paper

References

1Rettig, EM, D'Souza, G. Epidemiology of head and neck cancer. Surg Oncol Clin N Am 2015;24:379–96Google Scholar
2Ernster, JA, Sciotto, CG, O'Brien, MM, Finch, JL, Robinson, LJ, Willson, T et al. Rising incidence of oropharyngeal cancer and the role of oncogenic human papilloma virus. Laryngoscope 2007;117:2115–28Google Scholar
3Argiris, A, Karamouzis, MV, Raben, D, Ferris, RL. Head and neck cancer. Lancet 2008;371:1695–709Google Scholar
4Mehanna, H, Jones, TM, Gregoire, V, Ang, KK. Oropharyngeal carcinoma related to human papillomavirus. BMJ 2010;340:c1439Google Scholar
5Van Monsjou, HS, Balm, AJ, Van Den Brekel, MM, Wreesmann, VB. Oropharyngeal squamous cell carcinoma: a unique disease on the rise? Oral Oncol 2010;46:780–5Google Scholar
6D'Souza, G, Agrawal, Y, Halpern, J, Bodison, S, Gillison, ML. Oral sexual behaviors associated with prevalent oral human papillomavirus infection. J Infect Dis 2009;199:1263–9Google Scholar
7Hansson, BG, Rosenquist, K, Antonsson, A, Wennerberg, J, Schildt, EB, Bladström, A et al. Strong association between infection with human papillomavirus and oral and oropharyngeal squamous cell carcinoma: a population-based case-control study in southern Sweden. Acta Otolaryngol 2005;125:1337–44Google Scholar
8Gillison, ML, Broutian, T, Pickard, RK, Tong, Z, Xiao, W, Kahle, L et al. Prevalence of oral HPV infection in the United States, 2009–2010. JAMA 2012;307:693703Google Scholar
9Mehanna, H, Beech, T, Nicholson, T, El-Hariry, I, McConkey, C, Paleri, V et al. Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer--systematic review and meta-analysis of trends by time and region. Head Neck 2013;35:747–55Google Scholar
10Syrjänen, S. HPV infections and tonsillar carcinoma. J Clin Pathol 2004;57:449–55Google Scholar
11D'Souza, G, Kreimer, AR, Viscidi, R, Pawlita, M, Fakhry, C, Koch, WM et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007;356:1944–56Google Scholar
12Vidal, L, Gillison, ML. Human papillomavirus in HNSCC: recognition of a distinct disease type. Hematol Oncol Clin North Am 2008;22:1125–42Google Scholar
13Rosenquist, K, Wennerberg, J, Schildt, EB, Bladström, A, Göran Hansson, B, Andersson, G. Oral status, oral infections and some lifestyle factors as risk factors for oral and oropharyngeal squamous cell carcinoma. A population-based case-control study in southern Sweden. Acta Otolaryngol 2005;125:1327–36Google Scholar
14Allen, CT, Lewis, JS, El-Mofty, SK, Haughey, BH, Nussenbaum, B. Human papillomavirus and oropharynx cancer: biology, detection and clinical implications. Laryngoscope 2010;120:1756–72Google Scholar
15Braakhuis, BJ, Snijders, PJ, Keune, WJ, Meijer, CJ, Ruijter-Schippers, HJ, Leemans, CR et al. Genetic patterns in head and neck cancers that contain or lack transcriptionally active human papillomavirus. J Natl Cancer Inst 2004;96:9981006Google Scholar
16Pyeon, D, Newton, MA, Lambert, PF, den Boon, JA, Sengupta, S, Marsit, CJ et al. Fundamental differences in cell cycle deregulation in human papillomavirus-positive and human papillomavirus-negative head/neck and cervical cancers. Cancer Res 2007;67:4605–19Google Scholar
17Melkane, AE, Auperin, A, Saulnier, P, Lacroix, L, Vielh, P, Casiraghi, O et al. Human papillomavirus prevalence and prognostic implication in oropharyngeal squamous cell carcinomas. Head Neck 2014;36:257–65Google Scholar
18Psyrri, A, Gouveris, P, Vermorken, JB. Human papillomavirus-related head and neck tumors: clinical and research implication. Curr Opin Oncol 2009;21:201–5Google Scholar
19Ang, KK, Harris, J, Wheeler, R, Weber, R, Rosenthal, DI, Nguyen-Tân, PF et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010;363:2435Google Scholar
20Weinberger, PM, Yu, Z, Kountourakis, P, Sasaki, C, Haffty, BG, Kowalski, D et al. Defining molecular phenotypes of human papillomavirus-associated oropharyngeal squamous cell carcinoma: validation of three-class hypothesis. Otolaryngol Head Neck Surg 2009;141:382–9Google Scholar
21O'Rorke, MA, Ellison, MV, Murray, LJ, Moran, M, James, J, Anderson, LA. Human papillomavirus related head and neck cancer survival: a systematic review and meta-analysis. Oral Oncol 2012;48:1191–201Google Scholar
22Braakhuis, BJ, Brakenhoff, RH, Meijer, CJ, Snijders, PJ, Leemans, CR. Human papilloma virus in head and neck cancer: the need for a standardised assay to assess the full clinical importance. Eur J Cancer 2009;45:2935–9Google Scholar
23Venuti, A, Paolini, F. HPV detection methods in head and neck cancer. Head Neck Pathol 2012;6:6374Google Scholar
24Melkane, AE, Mirghani, H, Aupérin, A, Saulnier, P, Lacroix, L, Vielh, P et al. HPV-related oropharyngeal squamous cell carcinomas: a comparison between three diagnostic approaches. Am J Otolaryngol 2014;35:2532Google Scholar
25Lassen, P, Eriksen, JG, Hamilton-Dutoit, S, Tramm, T, Alsner, J, Overgaard, J. Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. J Clin Oncol 2009;27:1992–8Google Scholar
26St Guily, JL, Jacquard, AC, Prétet, JL, Haesebaert, J, Beby-Defaux, A, Clavel, C et al. Human papillomavirus genotype distribution in oropharynx and oral cavity cancer in France—the EDiTH VI study. J Clin Virol 2011;51:100–4Google Scholar
27Kreimer, AR. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 2005;14:467–75Google Scholar
28Taberna, M, Mena, M, Pavón, MA, Alemany, L, Gillison, ML, Mesía, R. Human papillomavirus-related oropharyngeal cancer. Ann Oncol 2017;28:2386–98Google Scholar
29Salameh, P, Zeenny, R, Salamé, J, Waked, M, Barbour, B, Zeidan, N et al. Attitudes towards and practice of sexuality among university students in Lebanon. J Biosoc Sci 2015;48:233–48Google Scholar
30Zhang, D, Pan, H, Cui, B, Law, F, Farrar, J, Ba-Thein, W. Sexual behaviors and awareness of sexually transmitted infections among Chinese university students. J Infect Dev Ctries 2013;7:966–74Google Scholar
31Lally, K, Nathan-V, Y, Dunne, S, McGrath, D, Cullen, W, Meagher, D et al. Awareness of sexually transmitted infection and protection methods among university students in Ireland. Ir J Med Sci 2015;184:135–42Google Scholar
32Mellin, H, Friesland, S, Lewensohn, R, Dalianis, T, Munck-Wikland, E. Human papillomavirus (HPV) DNA in tonsillar cancer: clinical correlates, risk of relapse, and survival. Int J Cancer 2000;89:300–4Google Scholar
33Gillison, ML, D'Souza, G, Westra, W, Sugar, E, Xiao, W, Begum, S et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst 2008;100:407–20Google Scholar
34Smith, EM, Ritchie, JM, Summersgill, KF, Klussmann, JP, Lee, JH, Wang, D et al. Age, sexual behavior and human papillomavirus infection in oral cavity and oropharyngeal cancers. Int J Cancer 2004;108:766–72Google Scholar
35Hobbs, CG, Sterne, JA, Bailey, M, Heyderman, RS, Birchall, MA, Thomas, SJ. Human papillomavirus and head and neck cancer: a systematic review and meta-analysis. Clin Otolaryngol 2006;31:259–66Google Scholar
36Paz, IB, Cook, N, Odom-Maryon, T, Xie, Y, Wilczynski, SP. Human papillomavirus (HPV) in head and neck cancer. An association of HPV 16 with squamous cell carcinoma of Waldeyer's tonsillar ring. Cancer 1997;79:595604Google Scholar
37Hafkamp, HC, Manni, JJ, Haesevoets, A, Voogd, AC, Schepers, M, Bot, FJ et al. Marked differences in survival rate between smokers and nonsmokers with HPV 16-associated tonsillar carcinomas. Int J Cancer 2008;122:2656–64Google Scholar
38Fakhry, C, Westra, WH, Li, S, Cmelak, A, Ridge, JA, Pinto, H et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008;100:261–9Google Scholar
39Fundakowski, CE, Lango, M. Considerations in surgical versus non-surgical management of HPV positive oropharyngeal cancer. Cancers Head Neck 2016;1:6Google Scholar
40Dayyani, F, Etzel, CJ, Liu, M, Ho, CH, Lippman, SM, Tsao, AS. Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC). Head Neck Oncol 2010;2:15Google Scholar
41Agrawal, Y, Koch, WM, Xiao, W, Westra, WH, Trivett, AL, Symer, DE et al. Oral human papillomavirus infection before and after treatment for human papillomavirus 16-positive and human papillomavirus 16-negative head and neck squamous cell carcinoma. Clin Cancer Res 2008;14:7143–50Google Scholar
42Lassen, P, Eriksen, JG, Krogdahl, A, Therkildsen, MH, Ulhøi, BP, Overgaard, M et al. The influence of HPV-associated p16-expression on accelerated fractionated radiotherapy in head and neck cancer: evaluation of the randomised DAHANCA 6&7 trial. Radiother Oncol 2011;100:4955Google Scholar
43Licitra, L, Perrone, F, Bossi, P, Suardi, S, Mariani, L, Artusi, R et al. High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol 2006;24:5630–6Google Scholar
44Lindel, K, Beer, KT, Laissue, J, Greiner, RH, Aebersold, DM. Human papillomavirus positive squamous cell carcinoma of the oropharynx: a radiosensitive subgroup of head and neck carcinoma. Cancer 2001;92:805–13Google Scholar
45Heiduschka, G, Grah, A, Oberndorfer, F, Kadletz, L, Altorjai, G, Kornek, G et al. Improved survival in HPV/p16-positive oropharyngeal cancer patients treated with postoperative radiotherapy. Strahlenther Onkol 2015;191:209–16Google Scholar
46Fakhry, C, Zhang, Q, Nguyen-Tan, PF, Rosenthal, D, El-Naggar, A, Garden, AS et al. Human papillomavirus and overall survival after progression of oropharyngeal squamous cell carcinoma. J Clin Oncol 2014;32:3365–73Google Scholar
47O'Sullivan, B, Huang, SH, Su, J, Garden, AS, Sturgis, EM, Dahlstrom, K et al. Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study. Lancet Oncol 2016;17:440–51Google Scholar
48Kofler, B, Laban, S, Busch, CJ, Lörincz, B, Knecht, R. New treatment strategies for HPV-positive head and neck cancer. Eur Arch Otorhinolaryngol 2014;271:1861–7Google Scholar
49Brockstein, BE, Vokes, EE. Head and neck cancer in 2010: maximizing survival and minimizing toxicity. Nat Rev Clin Oncol 2011;8:72–4Google Scholar
50Givens, DJ, Karnell, LH, Gupta, AK, Clamon, GH, Pagedar, NA, Chang, KE et al. Adverse events associated with concurrent chemoradiation therapy in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 2009;135:1209–17Google Scholar
51Guo, T, Eisele, DW, Fakhry, C. The potential impact of prophylactic human papillomavirus vaccination on oropharyngeal cancer. Cancer 2016;122:2313–23Google Scholar
52Suzich, JA, Ghim, SJ, Palmer-Hill, FJ, White, WI, Tamura, JK, Bell, JA et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci U S A 1995;92:11553–7Google Scholar